CDC Faces Leadership Vacuum Under Trump Administration | Healio News

The Centers for Disease Control and Prevention (CDC) is currently operating without a permanent director, a situation that has raised concerns among former agency officials. More than a year into President Trump’s second term, the leadership void is prompting questions about the agency’s ability to effectively address public health challenges.

“What we have is dangerous,” stated Tom Frieden, MD, MPH, former CDC director during the Obama administration. “Americans deserve health advice from health experts, not politicians, and lawyers.”

The situation stems from a series of appointments and dismissals. Last August, Jim O’Neill, a biotech investor and Deputy Secretary of Health and Human Services (HHS), was named acting director following the dismissal of Susan Monarez, a scientist with a PhD in microbiology and immunology. President Trump initially nominated Monarez to lead the agency in July 2025, but that nomination was withdrawn after a previous nominee was also pulled. Monarez’s tenure lasted just 29 days before she was dismissed by Secretary Kennedy for, among other reasons, refusing to fire senior CDC leaders.

Currently, over five months have passed since O’Neill assumed the role of acting director, with no indication of a permanent replacement on the horizon. HHS spokesperson Andrew Nixon characterized the period as a “necessary reset” for the agency, aimed at restoring trust and strengthening its core mission.

However, former CDC officials argue that the lack of permanent leadership jeopardizes the agency’s core functions. Anne Schuchat, MD, an internist and epidemiologist at the American Academy in Berlin and former CDC principal deputy director, emphasized the importance of having a designated leader representing the agency in key discussions at the HHS, White House, and congressional levels.

“Without a top director,” Schuchat explained, “the agency may not have representation in the key priorities for health and public health. There’s not a voice in the room…that is designated to be the leader.”

Legal considerations also come into play. Lawrence O. Gostin, JD, professor and founding director of the O’Neill Institute for National and Global Health Law at Georgetown, pointed to the Vacancies Reform Act, which limits the duration of temporary appointments in executive branch positions to 210 days. O’Neill will reach this limit by the end of March, potentially requiring a formal nomination or his removal from the position.

“Unless Congress or the courts push back, I don’t think Secretary Kennedy will be in any hurry to ensure a permanent director,” Gostin stated.

The White House has offered limited comment on the matter. Spokesperson Kush Desai stated that the administration “maintains continued confidence” in O’Neill’s work as acting director and that further personnel decisions would be announced in due time.

The absence of a permanent director also impacts the agency’s ability to prioritize and fund programs, according to Debra Houry, MD, MPH, who resigned as the CDC’s chief medical officer following Monarez’s dismissal. “You really need someone to set a vision, and that’s what’s lacking,” she said.

Houry also raised concerns about O’Neill’s level of engagement with CDC staff at its Atlanta headquarters, stating that, to her understanding, O’Neill had not visited the facility during his tenure as acting director. HHS spokesperson Nixon countered this claim, stating that O’Neill and principal deputy director Ralph Abraham, MD, are “actively engaged across the agency.”

Frieden reiterated the importance of a permanent director in upholding scientific integrity, transparency, and clear communication with the public. “The CDC director’s most important responsibilities are to lead the CDC so that it effectively protects Americans from health threats, both global and domestic…Those functions are essential to keep Americans safe.”

The situation highlights the potential consequences of political influence on public health agencies and the critical need for stable, expert leadership at the CDC.